DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,261,592 | +3.2% | 57,483 | -0.2% | 0.49% | +8.1% |
| Q2 2023 | $13,819,744 | -10.2% | 57,582 | -5.7% | 0.46% | -14.8% |
| Q1 2023 | $15,396,868 | -5.9% | 61,089 | -1.0% | 0.54% | -13.8% |
| Q4 2022 | $16,369,716 | +4.2% | 61,675 | +1.4% | 0.62% | -7.7% |
| Q3 2022 | $15,704,000 | +3.7% | 60,802 | +1.8% | 0.67% | +5.8% |
| Q2 2022 | $15,144,000 | +3.5% | 59,736 | +1.5% | 0.64% | +8.7% |
| Q1 2022 | $14,632,000 | -22.2% | 58,877 | +3.0% | 0.58% | -10.6% |
| Q4 2021 | $18,801,000 | +9.9% | 57,145 | +1.7% | 0.65% | -2.7% |
| Q3 2021 | $17,108,000 | +13.8% | 56,194 | +0.3% | 0.67% | +13.9% |
| Q2 2021 | $15,035,000 | +23.2% | 56,026 | +3.3% | 0.59% | +11.7% |
| Q1 2021 | $12,204,000 | +4.6% | 54,220 | +3.2% | 0.53% | -4.0% |
| Q4 2020 | $11,667,000 | +7.7% | 52,520 | +4.4% | 0.55% | -6.3% |
| Q3 2020 | $10,828,000 | +25.9% | 50,284 | +3.4% | 0.59% | +12.5% |
| Q2 2020 | $8,601,000 | +44.2% | 48,640 | +12.9% | 0.52% | +18.1% |
| Q1 2020 | $5,964,000 | +97.0% | 43,087 | +118.4% | 0.44% | +146.9% |
| Q4 2019 | $3,027,000 | +6.8% | 19,725 | +0.5% | 0.18% | 0.0% |
| Q3 2019 | $2,834,000 | +18.0% | 19,625 | +16.8% | 0.18% | +15.5% |
| Q2 2019 | $2,402,000 | +8.6% | 16,803 | +0.3% | 0.16% | +8.4% |
| Q1 2019 | $2,212,000 | +26.9% | 16,753 | -0.9% | 0.14% | +19.2% |
| Q4 2018 | $1,743,000 | -5.6% | 16,903 | -0.5% | 0.12% | +7.1% |
| Q3 2018 | $1,846,000 | +8.5% | 16,993 | -1.5% | 0.11% | -17.6% |
| Q2 2018 | $1,702,000 | +0.5% | 17,248 | -0.3% | 0.14% | 0.0% |
| Q1 2018 | $1,694,000 | +7.4% | 17,298 | +1.8% | 0.14% | +8.8% |
| Q4 2017 | $1,578,000 | +8.2% | 16,997 | 0.0% | 0.12% | +1.6% |
| Q3 2017 | $1,458,000 | +1.7% | 16,997 | 0.0% | 0.12% | -2.4% |
| Q2 2017 | $1,434,000 | -1.4% | 16,997 | 0.0% | 0.13% | +1.6% |
| Q1 2017 | $1,454,000 | +8.8% | 16,997 | -1.0% | 0.12% | +3.3% |
| Q4 2016 | $1,336,000 | +4.0% | 17,163 | +4.7% | 0.12% | 0.0% |
| Q3 2016 | $1,285,000 | -21.6% | 16,398 | +1.0% | 0.12% | -29.4% |
| Q2 2016 | $1,639,000 | +6.4% | 16,232 | 0.0% | 0.17% | -8.6% |
| Q1 2016 | $1,540,000 | +1.7% | 16,232 | -0.5% | 0.19% | +24.0% |
| Q4 2015 | $1,515,000 | +9.0% | 16,311 | 0.0% | 0.15% | -23.9% |
| Q3 2015 | $1,390,000 | -0.4% | 16,311 | 0.0% | 0.20% | +43.8% |
| Q2 2015 | $1,396,000 | +0.6% | 16,311 | -0.2% | 0.14% | +0.7% |
| Q1 2015 | $1,388,000 | -1.1% | 16,344 | -0.1% | 0.14% | -4.9% |
| Q4 2014 | $1,403,000 | +12.9% | 16,365 | 0.0% | 0.14% | +5.9% |
| Q3 2014 | $1,243,000 | -3.7% | 16,365 | -0.2% | 0.14% | -2.2% |
| Q2 2014 | $1,291,000 | +5.0% | 16,397 | 0.0% | 0.14% | -0.7% |
| Q1 2014 | $1,230,000 | -2.8% | 16,397 | -0.0% | 0.14% | -7.3% |
| Q4 2013 | $1,266,000 | +11.3% | 16,404 | +0.0% | 0.15% | -1.3% |
| Q3 2013 | $1,137,000 | +9.5% | 16,398 | +0.0% | 0.15% | -4.4% |
| Q2 2013 | $1,038,000 | – | 16,397 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |